Skip to main content
Kenji Cunnion, MD, Pediatric Infectious Disease, Norfolk, VA, Children's Hospital of The King's Daughters

KenjiM.CunnionMD

Pediatric Infectious Disease Norfolk, VA

Associate Professor, Pediatrics, Eastern Virginia Medical School

Dr. Cunnion is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Cunnion's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Pediatric Infectious Diseases, 1996 - 2000
  • Virginia Commonwealth University Health System
    Virginia Commonwealth University Health SystemResidency, Pediatrics, 1993 - 1996
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1993

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 1995 - 2024
  • NC State Medical License
    NC State Medical License 1997 - 2003
  • American Board of Pediatrics Pediatrics
  • American Board of Pediatrics Pediatric Infectious Diseases

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • Fellow (FAAP) American Academy of Pediatrics

Publications & Presentations

PubMed

Press Mentions

  • ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
    ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseFebruary 22nd, 2024
  • ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe Asthma
    ReAlta Life Sciences, Inc. Doses First Patient in Phase 1b Inhaled-LPS Challenge Clinical Trial to Support Development of RLS-0071 in Severe AsthmaJune 4th, 2022
  • Trial of RLS-0071 for Acute COPD Exacerbations Doses 1st Patient
    Trial of RLS-0071 for Acute COPD Exacerbations Doses 1st PatientMarch 5th, 2024

Grant Support

  • Staphylococcus Aureus Binds Factor H To Moderate Complement Host DefenseNational Institute Of Allergy And Infectious Diseases2009–2010
  • Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002–2006
  • Complement And The Clearance Of Staphylococcus AureusNational Institute Of Allergy And Infectious Diseases2002

Professional Memberships

Hospital Affiliations